Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 8 of 87, showing 5 Applications out of 432 total, starting on record 36, ending on 40

# Protocol No Study Title Investigator(s) & Site(s)

36.

ECCT/19/03/05   EPI-MAL-003 (Siaya)
    A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa (v1.0 11Oct2017): Site-specific protocol for Siaya County, western Kenya   
Principal Investigator(s)
1. Simon Kariuki
2. Martina Oneko
Site(s) in Kenya
1. Bondo sub-county (Siaya county)
2. Gem sub-county (Siaya county)
 
View

37.

ECCT/23/10/01   CROSSWALK Chronic (C)
    A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD) (CROSSWALK-c)   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Doreen Terry Karimi
Site(s) in Kenya
1. Gertrudes Childrens Hospital (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View

38.

ECCT/15/11/01   A5264
    A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy   versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of   Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS)   
Principal Investigator(s)
1. Dr. Victor Otieno Mudhune
Site(s) in Kenya
1. KEMRI CDC (Kisumu county)
 
View

39.

ECCT/09/06/02  
    A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy   plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual   Transmission of HIV-1 In Serodiscordant Couples   
Principal Investigator(s)
1. Lisa Ann Mills
Site(s) in Kenya
Kisumu, Kenya
 
View

40.

ECCT/20/07/02   RV 460 HIV Vaccine Trial
    A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenicity of   Priming with Env-C Plasmid DNA Vaccine Alone, with Different Adjuvants, or with an   Adjuvanted HIV Env gp145 C.6980 Protein Vaccine and Boosting with the Adjuvanted   HIV Env gp145 C.6980 Protein Vaccine with or without the Env-C Plasmid DNA Vaccine   in Healthy HIV Uninfected Adults in Kenya   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
KEMRI/US MRDA-A/K, KERICHO
 
View